Shares of Evotec SE (NASDAQ:EVO - Get Free Report) saw strong trading volume on Wednesday . 45,074 shares traded hands during mid-day trading, a decline of 16% from the previous session's volume of 53,452 shares.The stock last traded at $3.91 and had previously closed at $3.92.
Evotec Trading Down 0.8 %
The firm has a 50-day moving average of $4.30 and a 200-day moving average of $4.10. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Hedge Funds Weigh In On Evotec
Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Evotec in the 4th quarter worth $27,000. CSS LLC IL bought a new position in Evotec in the 4th quarter worth $50,000. Bank of America Corp DE raised its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares during the period. Lighthouse Investment Partners LLC bought a new position in Evotec in the 4th quarter worth $166,000. Finally, DCF Advisers LLC raised its holdings in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares during the period. 5.81% of the stock is owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
